Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $1.4 million.

  • NovaBay Pharmaceuticals' Total Current Liabilities fell 2701.61% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 2701.61%. This contributed to the annual value of $2.8 million for FY2024, which is 3354.37% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Total Current Liabilities of $1.4 million as of Q3 2025, which was down 2701.61% from $2.1 million recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Total Current Liabilities high stood at $6.1 million for Q2 2023, and its period low was $1.4 million during Q3 2025.
  • Moreover, its 5-year median value for Total Current Liabilities was $3.6 million (2024), whereas its average is $3.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 6587.37% in 2023, then tumbled by 5659.59% in 2024.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Total Current Liabilities stood at $3.4 million in 2021, then increased by 23.68% to $4.3 million in 2022, then rose by 0.49% to $4.3 million in 2023, then crashed by 33.54% to $2.8 million in 2024, then crashed by 49.07% to $1.4 million in 2025.
  • Its Total Current Liabilities stands at $1.4 million for Q3 2025, versus $2.1 million for Q2 2025 and $3.1 million for Q1 2025.